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\s=b\Although much is known about the virus believed by most
experts to be the cause of the acquired immunodeficiency syn-
drome and about its pathogenic actions, major areas of igno-
rance remain. Among these are the reasons for the varying time
between infection with human immunodeficiency virus and de-
velopment of acquired imunodeficiency syndrome, the relation-
ship between neurologic and medical aspects of the disease, the
time course of neuropsychological findings, and the prevalence
of psychiatric morbidity. We assessed 124 homosexual men who
were positive for human immunodeficiency virus and 84 who
were negative for the virus. In this article we describe the study
design, method of recruitment, and medical and demographic
characteristics of the cohort, which will be followed up for 5
years.(Arch Gen Psychiatry. 1991 ;48:120-123)
The acquired immunodeficiency syndrome (AIDS) is anillness that is transmitted by "high-risk" behavior and
results in widespread neuropsychiatrie morbidity,1"3 making it
important to study the behavioral and nervous system as¬
pects. Although much is now understood about the genetic
structure, life cycle, and pathogenesis of the agent that causesAIDS"—human immunodeficiency virus (HIV)—our only
tool in preventing infection remains promotion of behavioral
change. At present, we also know little about the relationship
of neuropsychiatrie symptoms to medical and immunologie
symptoms of HIV infection.
To address these issues, we began a 5-year follow-up study
of HIV-infected subjects in March 1988. This study provides
cross-sectional and longitudinal information from well-
matched HIV-seropositive and HIV-seronegative homosex¬
ual men and parenteral drug users.
Data are now available from the first evaluation of the
homosexual male cohort, thereby providing a cross-sectional
look at the relationship between HIV infection and behavior,
psychiatric morbidity, psychosexual function, and the ner¬
vous system at a relatively early stage in the disease.
Because of the multidisciplinary nature of this study, it was
thought best to report the baseline data on the homosexual
men in a series of related articles. This article will therefore
provide information on the method of recruitment, study
design, demographics, and medical status ofthe subjects. The
accompanying articles describe psychiatric/psychosocial and
neurologic/neuropsychological findings, respectively.
SUBJECTS AND METHODS
Recruitment of the homosexual male cohort was initiated in the
winter of 1987 and early spring of 1988. A single announcement in
each of two New York, NY, homosexual organization monthly news¬
letters, one paid newspaper announcement, and word of mouth drew
most of the study participants.
The baseline evaluations were completed between March 1988 and
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March 1989. lb be eligible for entry into the study, a subject had to
meet the following inclusion criteria: (1) homosexual or bisexual man
between 18 and 60 years of age, (2) previous HIV testing, including
knowing the test result for at least 1 month before study entry, (3) not
having self-administered parenteral drugs more than 10 times since
1981, and (4) not having any of the infections or tumors classified as
meeting criteria for AIDS according to the Centers for Disease
Control (CDC) National Surveillance Criteria.7
We made some exceptions to CDC criteria for AIDS before start¬
ing the study. Because we wished to assess nervous system abnor¬
malities independently, we did not exclude subjects from study entry
because of neuropsychological impairment even though the CDC
criteria that were revised between the time our protocol was de¬
signed and the beginning of field work included dementia as sufficient
to warrant a diagnosis of AIDS.8 We also began our study before this
revision of CDC criteria came to include "constitutional symptoms,"
such as weight loss, persistent diarrhea, night sweats, and fatigue, as
AIDS diagnoses. Subjects with these symptoms were, therefore, not
excluded. Finally, because the clinical distinction between oral and
esophageal candidiasis is difficult to make on routine physical exami¬
nation, we did not follow CDC criteria by excluding men with esopha¬
geal candidiasis as meeting the criteria for AIDS. The reason for
excluding subjects who already had AIDS was to ensure that we
began our study with relatively medically asymptomatic subjects.
The reason for requiring that all subjects already know their HIV
status before study entry was that at the time the study began (1987)
we did not wish to be in the position ofappearing to encourage testing.
The decision to have an HIV test is a highly individual one; knowing
HIV status may help a person obtain treatment early in the course of
infection but may also subject the individual to discrimination and
social isolation. Since 1987, with increased ability to treat HIV infec¬
tion and its consequent opportunistic infections, many authorities
have recommended early HIV testing.
Subjects arrived at the clinic at the New York State Psychiatric
Institute, New York, at 8:30 AM for the assessment day. They first
met with the project director for explanation of the procedures and to
give informed consent. Next, the subject met with one of the project
research nurses, who offered pre-HIV test counseling and obtained
the following information: a complete medical history with the use ofa
semistructured interview, devised by our group, that focuses on
HIV-related medical symptoms; a demographic questionnaire, also
devised by our group, that assesses socioeconomic status, living
arrangements, and religious affliations; vital signs; and blood for the
following tests: complete blood cell count, platelet count, T-cell sub¬
set enumeration, p24 antigen level, and acid-labile interferon- titer.
We also obtained blood for confirmatory HIV testing, which was done
by enzyme-linked immunosorbent assay and Western blot by the
New York City Health Department.
After seeing the nurse, subjects underwent five separate assess¬
ments as follows: (1) a physical examination conducted by a physician,
focusing on HIV-related signs; (2) a neurologic examination, conduct¬
ed by a neurologist; (3) a neuropsychological test battery; (4) struc¬
tured and semistructured psychiatric and psychosocial interview
conducted by trained interviewers; and (5) structured and semistruc¬
tured psychosexual interview.
Further details about the psychiatric/psychosocial and neurologic/
neuropsychological assessments are found in the accompanying arti¬
cles. The physical examination, neurologic examination, and neurop¬
sychological tests were all performed without knowledge of the sub¬ject's HIV status. The issues surrounding blindedness in conducting
psychiatric interviews are more complex and are discussed in one of
the accompanying articles.
We devised two systems for staging HIV infection. The first is a
four-tier system. On the basis of the medical history and physical
examination alone, HIV-seropositive subjects were assigned a num¬
ber from 0 to 39. A score of 0 to 9 represents a seropositive but
physically asymptomatic subject (ie, with no physical symptoms
assumed to be related to HIV infection that in themselves are severe
enough to warrant clinical attention). A score of 10 to 19 represents a
seropositive subject with mild medical symptoms (history or evi¬
dence of generalized lymphadenopathy or any clinically significant
physical symptoms not meeting criteria for stage III, eg, diarrhea for
2 weeks, fever for 2 weeks, or fatigue every other day for 1 month). A
score of 20 to 29 represents a seropositive subject with serious
symptoms, including a history or evidence ofany of the following: oral
Table 1 .—Demographic Characteristics*
Positive Negative
HIV HIV
(N = 124) (N =84)
Age, y 38.4±8.2 37.7±8.9 0.55 NS
Socioeconomic status(Hollingshead) 49.2±12.4 53.1 ±9.3 2.61 .01








*HIV indicates human immunodeficiency virus; NS, not significant.
or esophageal thrush, night sweats for more than 30 days, fever for
more than 30 days, loss of more than 10% of body weight, diarrhea for
more than 30 days, fatigue for more than 30 days, oral hairy leukopla-
kia, pulmonary tuberculosis, Salmonella septicemia, pneumococcal
bacteremia, herpes zoster, Haemophilus influenzae bacteremia, and
idiopathic thrombocytopenic purpura. A score of30 to 39 represents a
subject with AIDS, ie, seropositive with opportunistic infections or
secondary cancer. By definition, no subject with a score of30 or above
was entered in the study. Within each scoring decade, the examining
physican was free to assign a score using subjective judgment of
severity of medical signs and symptoms. The three examining physi¬
cians (R.K., J.D., and J.M.G.) later reviewed all of the medical
histories, examinations, and medical stage scores in a conference.
The second system involves a 20-item symptom checklist. These 20
items represent common signs and symptoms of HIV infection (but
not AIDS) found on physical examination and/or by medical history.
The time frame for the presence of symptoms identified by history
was usually the 3-month period before the baseline assessment. The
score on the checklist is simply the number of items recorded for the
subject at baseline assessment.
Blood samples were always drawn in the morning. They were then
immediately transported to the laboratory for HIV test (by enzyme-
linked immunosorbent assay with Western blot confirmation), T-cell
subset enumeration (by fluorescent cell sorter [EPIC-C, Coulter
Electronics, Hialeah, Fla]), p24 antigen assay (by standard kit [Du¬
pont, Wilmington, Del]), and acid-labile interferon- titer (methods
available on request).
At the conclusion of the day, subjects again met with the research
nurse and project director for debriefing. At this time subjects were
also given counseling about risk reduction, and a decision was made
whether the subject needed referral for medical or psychiatric care.
Subjects were then paid $10 per hour for their time and given an
appointment to return in 6 months.
RESULTS
A total of 215 men underwent the baseline assessment. Seven of
these were dropped from data analysis for the following reasons: four
subjects were found to have a history of serious neurologic disorder
preceding the beginning of the HIV epidemic and therefore unrelated
to HIV infection (one of the four had a seizure disorder and the other
three had Tourette's syndrome; the interpretation of neurologic and
neuropsychological data for these patients was believed to be too
confounded by the preexisting illness), one subject was blind and
therefore unable to complete the neuropsychological tests, one pa¬
tient was found to have an opportunistic infection characteristic of
AIDS at the time of the baseline assessment, and one subject had a
history ofrecent parenteral drug abuse that was not ascertained until
the psychiatric interview was conducted.
The remaining 208 subjects are the subject of these reports. One
hundred twenty-four were HIV positive and 84 were HIV seronega¬
tive. Table 1 shows the age, ethnicity, and Hollingshead socioeconom-
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Symptom (N = 124) (N = 84) x2f
Herpes (oral/genital) (ever) 67 36 2.50 NS
Oral candidiasis (ever) 38 6 15.20 .001
Lymphadenopathy (by
examination presently) 34 7 10.35 .002
Nonallergic body rash (Hx) 28 9 4.04 .05
Shingles (ever) 28 4 10.88 .001
Sinusitis (Hx) 18 10 0.11 NS
Leukoplakia or thrush (by
examination presently) 17 0 10.78 .001
Fever (Hx) 9 0 4.74 .05
Night sweats (Hx) 8 1 2.20 NS
Rash or scaling around
eyes(Hx) ' 7 1 1.62 NS
Diarrhea (Hx) 6 1 1.08 NS
Psoriasis (Hx) 5 2 0.06 NS
Shortness of breath (Hx) 4 5 0.36 NS
Easy bruising (Hx) 4 1 0.23 NS
Sore throat (Hx) 4 0 1.32 NS
Persistent cough (Hx) 2 1 0 NS
Meningitis (Hx) 1 2 0.12 NS
Hair loss (Hx) 1 0 0 NS
Pneumonia (Hx)
Weight loss (>10%) (Hx)
*SCS-20 indicates 20-item symptom checklist; HIV, human immunodefi¬
ciency virus; NS, not significant; and Hx, history during the last 3 months.
fWith Yates' correction.
ic status9 by serologie status for these subjects. The HIV-positive and
HIV-negative subjects were obviously well matched for all of these
variables. Although socioeconomic status was significantly higher for
the HIV-negative subjects (53.2) than for the HIV-positive subjects(49.1), the difference is clearly very small.
Forty-nine of the 124 seropositive men had medical stage scores
between 0 and 9 (asymptomatic); 29 had scores from 10 to 19 (mild
symptoms); and 46 had scores from 20 to 29 (moderate symptoms,
AIDS-related complex). The mean stage score was 12.5 ± 9.0, corre¬
sponding to a group with only mild medical symptoms.
The mean number of symptoms on the 20-item symptom checklist
was 2.1 ± 1.6. As indicated in Table 2, the most common symptoms
were a history of oral/genital herpes, a history of oral candidiasis,
enlarged lymph nodes, nonpsoriatic rash, history of herpes zoster(shingles) infection, sinusitis, oral leukoplakia or thrush by examina¬
tion, persistent fever, night sweats, rash around the eyes, and diar¬
rhea. It should be noted that by  2 statistic, five of these—diarrhea,
history of oral/genital herpes, night sweats, rash around the eyes,
and sinusitis—were not statistically more common in HIV-positive
than HIV-negative subjects (Table 2). This medical symptom pattern
indicates that the HIV-positive subjects represented a range of
medical severity but overall were a relatively mildly symptomatic
group.
Table 3 shows comparisons of baseline immunologie data between
HIV-positive and HIV-negative subjects. As expected, the HIV-
positive subjects had significantly fewer total lymphocytes, fewer
platelets, fewer CD4+ lymphocytes, lower CD4/CD8 ratio, and moreCD8+ lymphocytes than did HIV-negative subjects. The mean CD4
number for the HIV-positive group was 0.405 ± 0.223  109/L, and the
mean CD4/CD8 ratio was 0.56 ± 0.35.
Immunologie signs of advanced HIV illness include CD4 count less
than 0.2 x 10 /L, presence of p24 antigen in serum in an amount
greater than or equal to 30 pg/mL,10 and acid-labile interferon- titer
greater than or equal to 1:32. " Table 4 shows the number of subjects
Table 3.—Immunologie Measures*
HIV Positive, HIV Negative,
Mean ± SD Mean ± SD(N) (N) t
CD4, x10»/L 0.405 + .0223 0.833 + 0.267 12.50 .000(123) (84)
CD8, x10»/L 0.838 + 0.448 0.539 + 0.203 6.49 .OOOf(123) (84)
CD4/CD8 ratio 0.56 + 0.35 1.67±0.60 15.17
.OOOf(123) (84)
Total Lymphocytes, 1.815 + 0.676 2.019±0.052 2.43 .016f
x109/L (123) (84)
Platelets, x10»/L 202 + 52 254 ±61 6.39 .000(119) (82)
*HIV indicates human immunodeficiency virus.
fSeparate variance estimate.
Table 4.
—Immunologie Measures Indicating Advanced
Infection*
No. (%)
HIV Positive NIV Negative
p24 Antigen(>30pg/mL) 14/124 (11) 0/84 (0) 10.05 .002
Interferon =  
(>1:32) 4/124 (3) 0/84 (0) 1.32 NS
CD4(<0.2x10»/L) 19/123 (15) 1/84 (1) 10.05 .002
*HIV indicates human immunodeficiency virus; NS, not significant.
in our cohort who had these findings at baseline. Again, the relatively
few subjects who had these signs indicates that this group of patients
in general was relatively early in disease progression. It is interesting
to note that one of our HIV-negative subjects had a low CD4 count.
This subject was HIV negative by enzyme-linked immunosorbent
assay and Western blot, and therefore we considered him HIV nega¬
tive in all data analyses. It is possible that he was indeed a carrier of
HIV who will be so identified when the polymerase chain reaction test
is performed.12 On the other hand, low CD4 counts can occur tran¬
siently because of other infections.I3
A few of our HIV-positive subjects were taking, at baseline, a
variety of prescribed and nonprescribed drugs specifically aimed at
treating HIV infection. These included zidovudine (formerly azidoth-
ymidine or AZT), AL721, pentamidine, acyclovir, and diethyldithio-
carbamate. Only seven of the 124 seropositive subjects were taking
zidovudine.
COMMENT
Several points can be made about the cohort ofhomosexual
men under study in the follow-up project. Recruitment was
easy. A few advertisements and several talks to community
groups were all that was needed to fill the cohort quickly. This
indicates that our cohort is probably composed of relatively
well-connected homosexual and bisexual men.
We recognize that our sample may not represent the broad
populations that are affected by HIV, or even the homosexual
community as a whole. The study also suffers from the usual
bias of volunteerism. Given these limitations on generalizabi-
lity, we believe this cohort provides useful information be¬
cause it is composed of well-matched HIV-positive and HIV-
negative men and therefore gives a picture of the impact of
HIV infection at an early stage of illness. Furthermore, by
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studying a relatively small but homogeneous group, we were
able to obtain a great deal of in-depth information from an 8-
hour assessment that would be impossible to gather ifa larger
sample were involved. Studies of HIV-infected homosexual
and bisexual men of lower socioeconomic status and minority
groups are clearly lacking, and we hope to address this in
future work.
The accompanying articles have two main purposes. First,
within each domain, they evaluate the prevalence ofpatholog¬
ic findings in HIV-positive subjects compared with HIV-
negative subjects. Included in this goal is the examination of
whether psychiatric or neuropsychological symptoms are
more prevalent among HIV-infected subjects and therefore
may be the result of central nervous system infection by HIV.
Second, the articles examine several hypotheses concern¬
ing the relationships between psychiatric/psychosocial patho¬
logic findings and neurologic/neuro-psychological impairment
on the one hand and medical and immunologie complications of
HIV infection on the other. It is possible that some of the
factors we assess are actually "cofactors" that influence dis¬
ease progression. The literature suggests that stress and
psychiatric illness can lead to impaired immunologie function
and lower resistance to infection.14 This literature, reviewed
extensively elsewhere,16 also documents the mounting evi¬
dence of direct communication and reciprocal influence be¬
tween the central nervous system and the immune system.
There is absolutely no proof at present, however, that any
psychological factor influences the course of HIV infection.
Our study is designed at baseline and through the 5 years of
follow-up to evaluate this possibility.
This study was supported by HIV Center for Clinical and Behavioral Studies
grant MH-43520 and Research Scientist Development Award MH-00416 (Dr
Gorman) from the National Institute of Mental Health, Bethesda, Md.
We wish to acknowledge the contributions of Richard Neugebauer, Zena
Stein, Michael Grieco, Mohan Reddy, Elena Klein, Joan McKinnon, RN, Ronda
Friedman, RN, and Barbara Barnett.
References
1. Harper ME, Marselle LM, Gallo RC, Wong-Staal F. Detection of lympho-
cytes expressing human T-lymphotropic virus type III in lymph nodes and
peripheral blood from infected individuals by in situ hydridization. Proc Natl
Acad Sci U S A. 1986;83:772.
2. Shaw GM, Harper ME, Hahn BH, Epstein LG, Gajdusek DC, Price RW,
Navia BA, Petito CK, O'Hara CJ, Groodman JE, Cho ES, Oleske JM, Wong\x=req-\
Staal F, Gallo RC. HTLV-III infection in brains of children and adults with
AIDS encephalopathy. Science. 1985;227:177-182.
3. Price RW, Brew B, Sidtis J, Rosenblum M, Scheck AC, Cleary P. The
brain in AIDS: central nervous system HIV-1 infection and AIDS dementia
complex. Science. 1988;239:586-592.
4. Bowen DL, Lane HC, Fauci AS. Immunopathogenesis of the acquired
immunodeficiency syndrome. Ann Intern Med. 1985;103:704-709.
5. Rosenberg ZF, Fauci AS. Immunopathogenic mechanisms of HIV infec-
tion. Clin Immunol Immunopathol. 1989;50:S149-156.
6. Maddon P, Dalgleish A, McCougal J, Clapha P, Weiss RA, Axel R. The t4
gene encodes the AIDS virus receptor and is expressed in the immune system
and the brain. Cell. 1986;47:333-348.
7. Centers for Disease Control. Classification system for human T-lympho-
tropic virus type III/lymphadenopathy-associated virus infections. MMWR.
1986;35:334-339.
8. Centers for Disease Control. Revision of the CDC surveillance case
definition for acquired immunodeficiency syndrome. MMWR. 1987;36:33-15S.
9. Hollingshead AB. Two Factor Index of Social Position. New York, NY:
Psychological Corp; 1957.
10. Allain JP, Laurian Y, Paul DA, Verroust F, Leuther M, Gazengel C,
Senn D, Larrieu MJ, Bosser C. Long-term evaluation of HIV antigen and
antibodies to p24 and gp41 in patients with hemophilia: potential clinical impor-
tance. N Engl J Med.1987;317:1114-1121.
11. Eyester ME, Goedert JJ, Poon M, Preble OT. Acid-labile alpha interfer-
on: a possible preclinical marker for the acquired immunodeficiency syndrome
in hemophilia. N Engl J Med.1983;309:583-586.
12. Rogers MF. Use of polymerase chain reaction for early detection of
human immunodeficiency virus in infants born to seropositive mothers. N Engl
J Med. 1989;320:1649-1654.
13. Williams RC, Koster FT, Kilpatrick KA. Alterations in lymphocyte cell
surface markers during various human infections. Am J Med. 1983;75:807-813.
14. Solomon GF. Psychoneuroimmunology: interactions between central
nervous system and immune system. J Neurosci Res. 1987;18:1-9.
15. GormanJM, Kertzner R. Psychoneuroimmunology and HIV infection. J
Neuropsychiatry Clin Neurosci. 1990;2:241-252.
Downloaded From: http://archpsyc.jamanetwork.com/pdfaccess.ashx?url=/data/journals/psych/12493/ by a Columbia University User  on 06/13/2017
